India finally achieves the 100-crore Covid-19 vaccination benchmark on October 21. PM Narendra Modi on the occasion expressed his gratitude to the doctors, nurses, and everyone who contributed to the success. Modi tweeted, "We are witnessing the triumph of Indian science, enterprise, and the collective spirit of 130 crore Indians." However, Modi was joined by Health Minister Mansukh Mandaviya as he engaged with hospital officials.
Courtesy: Deccan Herald
While speaking at a function, Tamil Nadu's Health Minister M Subramaniam on October 13 said that the state will become the first in India to administer COVID vaccine to children aged 2-18 years after the Centre's approval. Reportedly, the proposal to allow the use of Bharat Bitotech's Covaxin has been sent to the Drugs Controller General of India (DCGI). Tamil Nadu is also the first state to vaccinate pregnant women.
Courtesy: Zee News
Covaxin, Bharat Biotech's COVID-19 vaccine, was recommended by an expert panel on October 12 for use on children aged two to 18. The company has also received a positive response from the Central Drugs Standard Control Organisation (CDSCO) on its clinical trials. Reportedly, children received the same vaccination as adults in separate trials. However, the company is waiting to get the regulatory approvals to launch it in the market.
Under the ''Vaccine Maitri'' initiative, India started the export of vaccine doses to Myanmar, Nepal, Bangladesh, and Iran, media reports said on October 10. Repotedly, India sent 10 lakh doses of Covidsheild to Myanmar, Nepal, and Bangladesh. While Iran will receive three lakh doses of Covaxin. The initiative will also help India to fulfill its commitment towards COVAX to supply vaccine to poor countries.
The World Health Organization (WHO) has not yet granted Covaxin emergency use Authorization. It is India's domestically produced coronavirus vaccine. On October 5, the Strategic Advisory Group of Experts on Immunization (SAGE) will have a meeting to discuss the Emergency Use Listing (EUL) for Covaxin. The four-day meeting of the expert group to deliberate on policy recommendations began on October 4. Only six vaccine candidates have been… read-more
Courtesy: Hindustan Times
The latest section of the CoWIN website termed "International Travel Certificate" will now have the international version of the Covid-19 vaccination certificate. The international travel certificate will cover: registered date of birth, the number of doses received, vaccine name, type, manufacturer, and dosage dates. The certificate complies with the international criteria set out by the World Health Organization. The international… read-more
Courtesy: Republic World
Despite the fact that diseases are already on the rise in many regions, leaders from developing countries informed the United Nations General Assembly that affluent countries' COVID-19 vaccine stockpiling might develop new coronavirus strains. The Philippines has warned of a man-made vaccination shortage in poor nations. Peru said that international unity had failed, while Ghana condemned vaccine sovereignty. The unequal distribution of COVID… read-more
Indian Health Minister Mansukh Mandaviya, on September 20, announced that the Government has decided to re-initiate the export of COVID vaccines. Reportedly, WHO Chief Tedros Adhanom Ghebreyesus thanked India and called it an "Important Development" that is crucial for ensuring Vaccine equality across the globe. Earlier, owing to the deadly second wave COVID, India in April 2021, had to stop the shipments of vaccines.
Courtesy: The Hindu
The approval for Emergency Use Authorisation (EUA) of Covaxin, manufactured by Hyderabad-based Bharat Biotech, is now postponed to October 5, by World Health Organization (WHO). WHO's Strategic Advisory Group on Immunization is scheduled to meet on October 5 to grant Covaxin the EUA. A vaccination safety monitoring strategy will be updated on a global, regional, and national level. EUA will be proposed based on Covaxin's trials.
CEO of Serum Institute of India (SII), Adar Poonawalla addressed a virtual conference with Executive Chairperson of Biocon Biologics (BBL) Kiran Mazumdar Shaw to announce their strategic alliance on September 17. Reportedly, SII was looking to scale up its research facilities with BBL. Also, the alliance aims to increase the production of Covishield Vaccines from 160 million doses monthly to 200 million doses from October.
Courtesy: The Indian Express